血清标志物对甲胎蛋白阴性肝细胞癌诊断的研究进展  

Progress in research of serum markers for diagnosis of alpha-fetoprotein negative hepatocellular carcinoma

作　　者：王子阳 王宏宾[1] 刘晓旌 Wang Ziyang;Wang Hongbin;Liu Xiaojing(Department of General Surgery,Qinghai University Affiliated Hospital,Xining 810000,China)

机构地区：[1]青海大学附属医院普通外科学一科,西宁810000

出　　处：《中华临床医师杂志(电子版)》2024年第7期677-681,共5页Chinese Journal of Clinicians(Electronic Edition)

摘　　要：目前肝细胞癌(HCC)是我国第四位常见恶性肿瘤及第二位恶性肿瘤致死病因,严重威胁人民的生命和健康。早期诊断及治疗能显著提高肝癌患者的生存率并改善预后。血清生物标志物检测因操作简便,在肝癌的早期筛查和诊断中具有较大的临床应用价值。甲胎蛋白(AFP)是临床诊断肝细胞癌高度专一性的血清标志物,但在我国约30%~40%肝细胞癌患者的甲胎蛋白为阴性,这极大的限制了甲胎蛋白在肝细胞癌诊断方面的作用。近年来,人们发现的血清标志物,包括蛋白类标志物、酶类标志物、细胞因子类标志物、基因类标志物、抗原抗体类标志物能弥补甲胎蛋白在肝细胞癌中诊断的不足。因此,发现并应用新型血清标志物来提高甲胎蛋白阴性肝细胞癌的早期诊断率已成为临床医学的迫切需要。Hepatocellular carcinoma is currently the fourth most common malignant tumor and the second leading cause of cancer-related deaths in China,posing a serious threat to people's lives and health.Early diagnosis and treatment can significantly improve the survival rate and prognosis of liver cancer patients.The detection of serum biomarkers has significant clinical application value in early screening and diagnosis of liver cancer due to its simple operation.Alpha-fetoprotein is a highly specific serum biomarker for clinical diagnosis of hepatocellular carcinoma.However,in China,about 30%~40%of hepatocellular carcinoma patients test negative for alpha-fetoprotein,which greatly limits its role in the diagnosis of hepatocellular carcinoma.In recent years,the serum markers discovered by researchers,including protein markers,enzyme markers,cytokine markers,gene markers,and antigen/antibody markers,can compensate for the insufficiency of alpha-fetoprotein in hepatocellular carcinoma diagnosis.Therefore,the discovery and application of novel serum biomarkers has become an urgent need in clinical medicine in order to improve the early diagnosis rate of alpha-fetoprotein negative hepatocellular carcinoma.

关 键 词：血清标志物 甲胎蛋白阴性 肝细胞癌 诊断 

分 类 号：R735.7[医药卫生—肿瘤]